November 20, 2025

Here's how the PD-(L)1xVEGF bispecific race is looking so far

IntelME Verdict

Clinical Advancement

TL;DR

Promising PD-(L)1xVEGF bispecific antibodies, including Pumitamig and Ivonescimab, show positive clinical results in lung cancer trials, advancing with FDA designations and potential for improved outcomes.

Analysis

The positive clinical results of PD-(L)1xVEGF bispecific antibodies like Pumitamig and Ivonescimab in lung cancer trials, along with FDA designations and potential for improved outcomes, signify a significant step forward in developing novel treatments targeting immune checkpoint and angiogenesis pathways for challenging cancers.

Source

Endpoints News↗